417 completed, 108 terminated, 95 recruiting, 78 active not recruiting. 381 Phase 2, 268 Phase 1, 110 Phase 3, 54 Not applicable, 18 Early Phase 1.
Follow Fallopian Tube Neoplasms: new trials by email Literature Review of Fallopian Tube Neoplasms trials Research Report on Fallopian Tube Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Losartan and Paclitaxel in Platinum Resistant Ovarian Cancer losartan, Paclitaxel - Platinum Resistant Ovarian Cancer | Phase 2 | Not yet recruiting | Massachusetts General Hospital | 27 | 2027-02-01 | 2026-09-22 |
| Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care Maintenance Treatment After First-line (1L) Platinum-based Chemotherapy in Participants With Ovarian Cancer Rina-S, Bevacizumab - Ovarian Cancer | Phase 3 | Not yet recruiting | Genmab | 602 | 2026-11-01 | 2026-10-05 |
| Trastuzumab Rezetecan Plus Bevacizumab in Platinum-Sensitive Recurrent Ovarian Cancer Trastuzumab Rezetecan (SHR-A1811), Bevacizumab, Platinum-based chemotherapy - Ovarian Cancer, Fallopian Tube Cancers | Phase 2 | Not yet recruiting | Peking University Cancer Hospital & Institute | 53 | 2026-10-22 | 2026-10-01 |
| A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05) R-DXd, Bevacizumab, Carboplatin - Ovarian Cancer, Peritoneal Cancer | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 646 | 2026-10-07 | 2026-10-16 |
| Radiotherapy for Gynecologic Cancer With Up to 10 Active Metastatic Lesions Routine-care metastasis-directed radiotherapy - Cervical Cancer, Gynecologic Cancer | Recruiting | Affidea Nu-med Center of Oncological DIagnostics and Therapy | 500 | 2026-10-06 | 2026-10-20 | |
| A Study of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab as Maintenance Therapy in Second-Line Platinum-Sensitive Recurrent Ovarian Cancer (REJOICE-Ovarian03) R-DXd, Bevacizumab - Fallopian Tube Cancer, Primary Peritoneal Cancer | Phase 3 | Not yet recruiting | Daiichi Sankyo | 600 | 2026-10-01 | 2026-09-01 |
| Efficacy and Safety of BG-C9074 With Bevacizumab Compared With Bevacizumab in Adults With Ovarian, Fallopian Tube, or Primary Peritoneal Cancers BG-C9074, Bevacizumab - Epithelial Ovarian Cancer, Fallopian Tube Cancer | Phase 3 | Not yet recruiting | BeOne Medicines | 600 | 2026-10-01 | 2026-09-10 |
| Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer Torvutatug samrotecan, Bevacizumab - Platinum-sensitive Relapsed Epithelial Ovarian Cancer, Platinum-sensitive Relapsed Fallopian Tube Cancer | Phase 3 | Recruiting | AstraZeneca | 600 | 2026-09-24 | 2026-10-16 |
| A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04) R-DXd, Bevacizumab - Ovarian Cancer, Ovarian Neoplasms | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 802 | 2026-09-18 | 2026-10-21 |
| Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Homologous Recombination Deficiency (HRD) Negative Advanced Epithelial Ovarian Cancer Torvutatug samrotecan, Bevacizumab - Epithelial Ovarian Cancer | Phase 3 | Recruiting | AstraZeneca | 950 | 2026-09-16 | 2026-10-01 |
| IGFBP-2 Vaccine to Prevent Ovarian Cancer Progression in Patients With Serologic Detection of Recurrence pUMVC3-hIGFBP-2 Multi-epitope Plasmid DNA Vaccine, Carboplatin, Computed Tomography - Fallopian Tube Carcinoma, Ovarian Carcinoma | Phase 2 | Recruiting | University of Washington | 26 | 2026-09-16 | 2026-09-21 |
| Targeting Immune Modulation in High Grade Serous Carcinoma: Combined Effects of Chemotherapy and Atorvastatin Standard of Care + atorvastatin, Standard of Care (SOC) - Ovarian Cancer, Fallopian Tube Cancers | Phase 2 | Not yet recruiting | University of Colorado, Denver | 40 | 2026-09-01 | 2026-09-11 |
| Study of Supplemental Arginine With Chemotherapy and Immunotherapy in Platinum Resistant Ovarian, Fallopian Tube, and Peritoneal Cancer (Arginaid®) Oral Arginine, (R-Gene® 10) IV Arginine, Pembrolizumab - Platinum Resistant Ovarian Cancer, Fallopian Tube Cancers | Phase 1 | Not yet recruiting | Rebecca Arend | 24 | 2026-09-01 | 2026-10-15 |
| Molecular Ovarian Cancer Assessment in LatiNoAmerican PAtients Ovarian Cancer by FIGO Stage, Ovarian Cancer Stage III | Not yet recruiting | Latin American Cooperative Oncology Group | 320 | 2026-09-01 | 2026-08-25 | |
| A Real-world Study of Mirvetuximab Soravtansine (MIRV) in Ovarian Cancer Patients of Expression of Folate Receptor α（FRα） Mirvetuximab Soravtansine (MIRV) - Ovarian Cancer, Fallopian Tube Cancers | Not yet recruiting | NING LI-GYN | 400 | 2026-07-20 | 2026-07-24 | |
| IMMU-132 in TROP-2 Overexpressed Advanced and Relapsed Ovarian Cancer Sacituzumab govitecan monotherapy - Epithelial Ovarian Cancer, Fallopian Tube Cancers | Phase 1 | Not yet recruiting | Shanghai Gynecologic Oncology Group | 19 | 2026-07-01 | 2026-06-30 |
| A Study Comparing BL-M07D1 With Physician's Choice of Chemotherapy in Patients With HER2-Expressing Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer BL-M07D1, Liposomal Doxorubicin, Paclitaxel - Epithelial Ovarian Cancer, Fallopian Tube Cancer | Phase 3 | Not yet recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 404 | 2026-07-01 | 2026-06-29 |
| An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer in China Rina-S, Paclitaxel, Topotecan - Platinum-resistant Ovarian Cancer | Phase 3 | Recruiting | Genmab | 82 | 2026-06-26 | 2026-10-06 |
| Reirradiation and Total Ablative Strategies for Recurrent Gynecologic Cancer Reirradiation, Total Ablative Strategy - Recurrent Gynecologic Cancer, Recurrent Uterine Cancer | Recruiting | Affidea Nu-med Center of Oncological DIagnostics and Therapy | 500 | 2026-06-11 | 2026-10-16 | |
| Liposomal Irinotecan Plus Enlonstobart for Platinum-Resistant Recurrent Ovarian Cancer Liposomal Irinotecan - Platinum-resistant Recurrent Ovarian Cancer, Fallopian Tube Cancers | Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 30 | 2026-05-30 | 2026-05-18 |
Showing 20 of 827. Sign in to see all of them.
Ovarian Neoplasms (662) · Carcinoma, Ovarian Epithelial (290) · Endometrial Neoplasms (105) · Uterine Cervical Neoplasms (76) · Breast Neoplasms (62) · Neoplasms (58) · Peritoneal Neoplasms (52) · Recurrence (39) · Vulvar Neoplasms (39) · Brenner Tumor (38) · Carcinoma, Non-Small-Cell Lung (37) · Vaginal Neoplasms (37) · Stomach Neoplasms (34) · Pancreatic Neoplasms (29)
Female Urogenital Diseases (827) · Female Urogenital Diseases and Pregnancy Complications (827) · Genital Diseases (827) · Urogenital Diseases (827) · Adnexal Diseases (826) · Fallopian Tube Diseases (824) · Genital Diseases, Female (823) · Neoplasms by Site (823) · Urogenital Neoplasms (823) · Genital Neoplasms, Female (815) · Gonadal Disorders (781) · Endocrine System Diseases (780) · Endocrine Gland Neoplasms (779) · Neoplasms (769) · Ovarian Diseases (769)
Carboplatin (160) · Paclitaxel (156) · Bevacizumab (94) · Gemcitabine (50) · Taxes (48) · liposomal doxorubicin (48) · Topotecan (42) · Cisplatin (35) · pembrolizumab (34) · Cyclophosphamide (29) · olaparib (25) · Disulfides (24) · Immunoglobulin G (24) · Specimen Handling (21) · Docetaxel (20)
National Cancer Institute (NCI) (81) · Gynecologic Oncology Group (41) · M.D. Anderson Cancer Center (36) · Memorial Sloan Kettering Cancer Center (28) · Roswell Park Cancer Institute (16) · Dana-Farber Cancer Institute (15) · Mayo Clinic (15) · Masonic Cancer Center, University of Minnesota (13) · AGO Study Group (11) · Shanghai Gynecologic Oncology Group (11) · AstraZeneca (10) · AbbVie (9) · University Health Network, Toronto (9) · Eli Lilly and Company (8) · Merck Sharp & Dohme LLC (8)
United States (586) · Canada (85) · United Kingdom (73) · Spain (69) · Italy (56) · China (55) · Germany (54) · Australia (52) · Belgium (52) · France (52) · South Korea (50) · Japan (32) · Poland (25) · Israel (24) · Denmark (23)
Paul Sabbatini, MD (11) · Emese Zsiros (6) · Kunle Odunsi (6) · Shannon N Westin (6) · Ursula Matulonis, MD (6) · Amit Oza (4) · Amy D. Tiersten, MD (4) · Angeles A Secord, MD (4) · Dennis Chi, MD (4)
PMID 37185961, PMID 37407274, PMID 32379297, PMID 35170751, PMID 21941283, PMID 35397664, PMID 16239238, PMID 16394300, PMID 19238149, PMID 19949018, PMID 20818904, PMID 22002018, PMID 22204724, PMID 22204725, PMID 23810467, PMID 25218906, PMID 26588236, PMID 31685558, PMID 36459691, PMID 36608308, PMID 37227734, PMID 37364223, PMID 40132910, PMID 10623700, PMID 10628376, PMID 10793106, PMID 11181662, PMID 11309294, PMID 11331762, PMID 11459964, PMID 11533692, PMID 12082455, PMID 12082456, PMID 12205100, PMID 12217790, PMID 12241653, PMID 12460789, PMID 12829663, PMID 12860964, PMID 14615449, PMID 14645425, PMID 14656276, PMID 14701743, PMID 15131031, PMID 15327776, PMID 15367671, PMID 15661234, PMID 15665856, PMID 15699482, PMID 1581961
U10CA027469 (38), U10CA180868 (35), U10CA101165 (10), UM1CA186709 (8), 2023 (7), N01CM62203 (6), P30CA016056 (6), N01CM62201 (5), N01CM62209 (5), P50CA136393 (5), U10CA032102 (5), 2017 (4), 2019 (4), 2025 (4), N01CM00071 (4)